Abstract: The present invention is directed to multi-tyrosine kinase inhibitor compounds. The present invention is further directed to compositions comprising those compounds. Finally, the present invention is directed to methods of treating eye conditions including, but not limited to, diabetic background retinopathy, diabetic macular edema, diabetic proliferative retinopathy, diabetic macular edema with proliferative retinopathy, proliferative fibrovascular disease, diabetic macular edema with proliferative fibrovascular disease, retinopathy of prematurity, dry macular degeneration, dry macular degeneration with drusen and wet macular degeneration, using compounds and compositions of the invention.

Abstract: The invention generally relates to compositions for inducing vasoconstriction. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.

Abstract: The invention is directed to topical drug vehicle platform compositions for ophthalmological and dermatological use. These compositions comprise a means to sequester tears and an ophthalmological drug. The invention is further directed to methods of treating a spectrum of ocular surface disease epitheliopathies including but not limited to dry eye in a human or mammal. The invention is further directed to contact lenses, punctum plugs, pellets or any other device used to deliver drugs to the surface of the eye, coated or infused with compositions of the invention.

Abstract: The present invention relates to methods of reducing or eliminating brow ache when administering an ophthalmic drug comprising formulating and administering the ophthalmic drug with a surfactant and a viscosity enhancer to create a composition having a viscosity of about 25 centipoise or less at a shear rate of 1/1000 per second at 25 degrees Celsius and a viscosity of about 70 centipoise at shear rate of 1 per second at 25 degrees Celsius. The present invention further relates to methods of treating an eye condition selected from the group consisting of presbyopia, myopia, hyperopia and astigmatism without inducing brow ache comprising administering a composition comprising a miotic agent, a surfactant and a viscosity enhancer, wherein the composition has a viscosity of about 25 centipoise or less at a shear rate of 1/1000 per second at 25 degrees Celsius and a viscosity of about 70 centipoise or more at shear rate of 1 per second at 25 degrees Celsius.

Abstract: The invention provides compositions and methods for the treatment of presbyopia. The compositions comprise aceclidine hydrochloride, polysorbate 80, mannitol, anhydrous hypromellose, disodium edetate dihydrate and anhydrous sodium citrate and optionally brimonidine, benzalkonium chloride and/or sorbic acid.

Abstract: The present invention is directed to compositions containing low-dose brimonidine and either a second glaucoma drug, an anti-histamine or non-steroidal anti-inflammatory drug. The present invention is further directed to methods of treating glaucoma or allergies or reducing inflammation by administering compositions of the present invention.

Abstract: The invention provides methods for the treatment of myopia. The compositions preferably comprise aceclidine. The compositions optionally contain a surfactant, a viscosity agent, a polyol and/or a selective ?-2 adrenergic receptor agonist.

Abstract: The invention generally relates to compositions for inducing vasoconstriction. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.

Abstract: The invention is directed to a topical composition comprising one or more topical active ingredients, one or more nonionic surfactants, one or more viscosity enhancers, polyethylene glycol and menthol. The invention is further directed to a method of reducing or eliminating pain comprising applying a composition of the present invention to a subject in need thereof.

Abstract: The present invention is directed to compositions for and methods for the treatment of presbyopia, irregular astigmatism, and/or refractive error comprising from about 0.1% to about 4.0% w/v of a muscarinic agonistand from about 0.001% to about 0.1% w/v brimonidine.

Abstract: The invention is directed to compositions comprising polysorbate 80, poloxamer 407, poloxamer 188, polyoxyl 35 castor oil, hydroxypropyl gamma cyclodextrin, hydroxypropylmethylcellulose, polyethylene glycol 400, mannitol, magnesium chloride, sodium chloride and potassium sorbate. The invention is further directed to a method of treating dry eye comprising topically applying compositions of the present invention to the eye of a subject in need thereof.

Abstract: The invention provides compositions and methods for the treatment of presbyopia. The methods preferably comprise storing an aceclidine composition in a container having a headspace at a temperature from about 2 to about 8 degrees Celsius. The methods further comprise filling the container under an inert gas overlay and/or enclosing the container an anti-leaching material or disposing the container in a second container containing an anti-leaching material.

Abstract: The invention is directed to a topical composition comprising one or more topical active ingredients, one or more nonionic surfactants and one or more viscosity enhancers. The invention is further directed to a method of treating topical conditions comprising applying a composition of the present invention to a subject in need thereof.

Abstract: The present invention is directed to anti-viral compositions comprising zinc, optionally, an alpha-adrenergic receptor agonist, one or more nonionic surfactants and one or more viscosity enhancers. The present invention is further directed to methods of treating viral infections comprising administering compositions of the present invention to a subject in need thereof.

Abstract: The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine. The compositions optionally contain a surfactant and a viscosity agent.

Abstract: The invention generally relates to compositions for inducing vasoconstriction. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.

Abstract: The present invention is directed to compounds of the formula and salts or esters thereof. The present invention is further directed to ophthalmological compositions comprising a therapeutically effective amount of a compound of the present invention and one or more pharmaceutically acceptable excipients. The present invention is further directed to a methods of treating presbyopia or glaucoma or reducing hyperemia comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention.

Abstract: The present invention is directed to compositions containing low-dose brimonidine and a second glaucoma drug. The present invention is further directed to methods of treating glaucoma by administering compositions of the present invention.

Abstract: The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine. The compositions optionally contain a surfactant and a viscosity agent.

Abstract: The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine. The compositions optionally contain a surfactant and a viscosity agent.